These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31072729)

  • 21. Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients.
    Tanaka T; Yorozu A; Sutani S; Yagi Y; Nishiyama T; Shiraishi Y; Ohashi T; Hanada T; Saito S; Toya K; Shigematsu N
    Brachytherapy; 2018; 17(5):799-807. PubMed ID: 29936128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemical outcomes and predictive factors by risk group after permanent iodine-125 seed implantation: Prospective cohort study in 2,316 patients.
    Katayama N; Nakamura K; Yorozu A; Kikuchi T; Fukushima M; Saito S; Dokiya T
    Brachytherapy; 2019; 18(5):574-582. PubMed ID: 31153759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
    Mabjeesh NJ; Chen J; Stenger A; Matzkin H
    Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.
    Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment nomogram to predict the risk of acute urinary retention after I-125 prostate brachytherapy.
    Roeloffzen EM; van Vulpen M; Battermann JJ; van Roermund JG; Saibishkumar EP; Monninkhof EM
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):737-44. PubMed ID: 20888131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
    Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
    Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
    Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
    Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database.
    Okihara K; Yorozu A; Saito S; Tanaka N; Koga H; Higashide S; Kikuchi T; Nakano M
    Int J Urol; 2017 Jul; 24(7):518-524. PubMed ID: 28455847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy.
    Crook J; Toi A; McLean M; Pond G
    Brachytherapy; 2002; 1(3):131-7. PubMed ID: 15090275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant.
    Eade TN; Horwitz EM; Ruth K; Buyyounouski MK; D'Ambrosio DJ; Feigenberg SJ; Chen DY; Pollack A
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):338-45. PubMed ID: 18207665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy.
    Moman MR; van der Poel HG; Battermann JJ; Moerland MA; van Vulpen M
    Brachytherapy; 2010; 9(2):119-25. PubMed ID: 19850536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iodine-125 brachytherapy for localized prostate cancer and urinary morbidity: a prospective comparison of two seed implant methods-preplanning and intraoperative planning.
    Matzkin H; Kaver I; Stenger A; Agai R; Esna N; Chen J
    Urology; 2003 Sep; 62(3):497-502. PubMed ID: 12946754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
    J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity.
    Devisetty K; Zorn KC; Katz MH; Jani AB; Liauw SL
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1060-5. PubMed ID: 20045267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
    Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
    Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation.
    Crook J; McLean M; Catton C; Yeung I; Tsihlias J; Pintilie M
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):453-60. PubMed ID: 11872292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].
    Zebentout O; Apardian R; Beaulieu L; Harel F; Martin AG; Vigneault E
    Cancer Radiother; 2010 Jun; 14(3):183-8. PubMed ID: 20418145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive factors for acute and late urinary toxicity after permanent interstitial brachytherapy in Japanese patients.
    Tanimoto R; Bekku K; Katayama N; Kobayashi Y; Ebara S; Araki M; Takemoto M; Yanai H; Nasu Y; Kumon H
    Int J Urol; 2013 Aug; 20(8):812-7. PubMed ID: 23294011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.